Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Grassley Seeking Zyprexa Lawsuit Documents

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Senate Finance Committee ranking member requests all documents and materials relating to product liability litigation involving Lilly’s antipsychotic by April 25.

You may also be interested in...



Utah Attorney General Sues Lilly For Medicaid Funds Spent On Zyprexa

State also has assumed cost of caring for recipients who consumed prescriptions that were “actively harmful,” AG claims.

Utah Attorney General Sues Lilly For Medicaid Funds Spent On Zyprexa

State also has assumed cost of caring for recipients who consumed prescriptions that were “actively harmful,” AG claims.

Lilly Expects FDA Action On Symbyax For Treatment-Resistant Depression In Second Half

After receiving an “approvable” letter in March for treatment-resistant depression, firm says it is working with the agency to determine labeling and post-marketing commitments.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By